Vote Scores

Home / Companies / VYNE Therapeutics Inc. / 12 Dec 2024

Meeting · year to 30 June 202536 filers reporting

VYNE Therapeutics Inc.: meeting of 12 Dec 2024

Votes reported on Form N-PX, item by item

36 Form N-PX filers reported votes at the VYNE Therapeutics Inc. meeting of 12 Dec 2024. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

2 nominees; 100.0% of reported votes for; no filer withheld from or voted against at least one nominee.

16 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management4 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

44 vote records from 36 filers. 14 of the 32 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.

50.0% for38.9% against11.1% other43.8% against management36 filers81.0% for19.0% against19.0% against management6,115,252 reported shares
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 28 filers; for: 2 filers; two years: 1 filer; not applicable: 1 filer.

42 vote records from 34 filers. 1 of the 31 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

5.9% for0.0% against94.1% other3.2% against management34 filers0.0% for0.0% against100.0% other0.0% against management5,669,818 reported shares
4

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

8 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management4 filers100.0% for0.0% against0.0% against management567,172 reported shares
5

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

8 vote records from 4 filers. 0 of the 4 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management4 filers100.0% for0.0% against0.0% against management567,172 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Pay-vote frequency4. Auditor
VanguardForForSplit or no voteFor
BlackRock and iSharesForAgainst *Split or no voteFor
FidelityForAgainst *Split or no voteFor
State Street and SPDRNo reportForSplit or no voteNo report
EquitableForAgainst *Split or no voteFor
Goldman SachsNo reportSplit or no voteSplit or no voteNo report
Northern Trust and FlexSharesNo reportForSplit or no voteNo report
BNY MellonNo reportAgainst *Split or no voteNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the VYNE Therapeutics Inc. meeting?

36 Form N-PX filers reported votes at the meeting of 12 Dec 2024. On say-on-pay, 14 of 32 voted against management (43.8%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by VYNE Therapeutics Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for VYNE Therapeutics Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing VYNE Therapeutics Inc. with a meeting date within three days of 12 Dec 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.